iRadimed (IRMD) Earnings Date, Estimates & Call Transcripts $66.17 +7.83 (+13.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$66.05 -0.12 (-0.18%) As of 08/1/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock iRadimed Earnings Summary iRadimed released Q2 2025 earnings on August 1, 2025, reporting an EPS of $0.45, which hit the consensus estimate of $0.45. Quarterly revenue was reported to be $20.41 million, above analysts' expectations of $20.01 million. With a trailing EPS of $1.55 and a P/E Ratio of 42.69, iRadimed's earnings are expected to grow 20.48% next year, from $1.66 to $2.00 per share. Latest Q2 Earnings DateAug. 1EstimatedConsensus EPS (Aug. 1) $0.45 Actual EPS (Aug. 1) $0.45 Actual Revenue (Aug. 1) $20.41MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get iRadimed Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iRadimed and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataIRMD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.IRMD Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. iRadimed Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $1.66 EPSNext Year EPS Consensus Estimate $2.00 EPS iRadimed Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/1/2025Q2 2025$0.45$0.45-$0.45$20.01M$20.41M2/13/2025Q4 2024$0.45$0.40 -$0.05$0.40$19.09M$19.39M8/1/2024Q2 2024$0.33$0.38+$0.05$0.38$17.70M$17.93M5/2/2024Q1 2024$0.31$0.32+$0.01$0.32$17.26M$17.60M2/8/2024Q4 2023$0.37$0.36 -$0.01$0.36-$17.45M11/3/2023Q3 2023$0.34$0.40+$0.06$0.40$16.21M$16.51M8/3/2023Q2 2023$0.28$0.33+$0.05$0.33$15.70M$16.13M iRadimed Earnings - Frequently Asked Questions When did iRadimed announce their last quarterly earnings? iRadimed (NASDAQ:IRMD) last announced its quarterly earning data on Friday, August 1, 2025. Learn more on IRMD's earnings history. What guidance has iRadimed issued on next quarter's earnings? iRadimed issued an update on its third quarter 2025 earnings guidance on Friday, August, 1st. The company provided EPS guidance of 0.450-0.490 for the period, compared to the consensus estimate of 0.435. The company issued revenue guidance of $20.5 million-$20.9 million, compared to the consensus revenue estimate of $19.8 million. Did iRadimed beat their earnings estimates last quarter? In the previous quarter, iRadimed (NASDAQ:IRMD) reported $0.45 earnings per share (EPS) to hit the analysts' consensus estimate of $0.45. Learn more on analysts' earnings estimate vs. IRMD's actual earnings. How can I listen to iRadimed's earnings conference call? The conference call for iRadimed's latest earnings report can be listened to online. Listen to Conference Call How can I read iRadimed's conference call transcript? The conference call transcript for iRadimed's latest earnings report can be read online. Read Transcript How much revenue does iRadimed generate each year? iRadimed (NASDAQ:IRMD) has a recorded annual revenue of $73.24 million. How much profit does iRadimed generate each year? iRadimed (NASDAQ:IRMD) has a recorded net income of $19.23 million. IRMD has generated $1.55 earnings per share over the last four quarters. What is iRadimed's price-to-earnings ratio? iRadimed (NASDAQ:IRMD) has a trailing price-to-earnings ratio of 42.69 and a forward price-to-earnings ratio of 39.86. What is iRadimed's EPS forecast for next year? iRadimed's earnings are expected to grow from $1.66 per share to $2.00 per share in the next year, which is a 20.48% increase. More Earnings Resources from MarketBeat Related Companies Warby Parker Earnings LivaNova Earnings National Vision Earnings LeMaitre Vascular Earnings Liquidia Technologies Earnings CONMED Earnings Enovis Earnings Cadre Earnings NovoCure Earnings Artivion Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Microsoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag? This page (NASDAQ:IRMD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iRadimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share iRadimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRMD Stock Alerts